key: cord-0803828-yysl8vli authors: Singhal, Tanu; Shah, Sweta; Naik, Reshma; Kazi, Amreen; Thakkar, Pooja title: Persistence of SARS-CoV-2 antibodies beyond 6 months in health care workers in Mumbai date: 2021-02-26 journal: Indian J Med Microbiol DOI: 10.1016/j.ijmmb.2021.02.003 sha: 7c6f6fe454b6b7f6d5cb17bd6d1459519a6be9b2 doc_id: 803828 cord_uid: yysl8vli nan Keywords: SARS-CoV-2; antibodies; long term Dear Editor It is the generally believed that antibodies against SARS-CoV-2 decline over time [1] . We have previously reported seroprevalence rates of SARS-CoV-2 binding antibodies in health care workers (HCW) at our hospital in June 2020 [2] . In that cohort of 244 HCW, 49 HCW had tested positive; 30 by Roche ECLIA (IgG and IgM) and 17 by Abbott CLIA (IgG). Of the infected HCW, 41 had mild symptoms and 8 were asymptomatic. The mildly symptomatic HCW had an uneventful recovery. We now report the follow up serostatus of these HCW in Dec 2020. Forty seven of 49 HCW serostatus was estimated by Roche ECLIA after taking informed consent. Forty-six HCW (98%) were still seropositive. Eighty one percent had actually rise in the optical density (OD) while 19% had reduction in OD. The persistence/ increase in antibodies seen in our study population is in contrast to most studies that report decline in binding IgM, IgG and neutralizing antibody titers over time in patients recovering from COVID-19 [1, 3, 4] . Even after discounting the fact that some of this increase may be due to testing of HCW early in the course of their illness the first time, that OD is just a surrogate of the actual antibody titers and that these are binding and not neutralizing antibodies, the study results are significant. We hypothesize that this persistence/increase in antibodies is possibly due to boosting following repeated natural exposures. Vaccination against COVID-19 with two doses is also based on the prime-boost In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution) Time frame: Since the initial planning of the work 1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. ____None Time frame: past 36 months 2 Grants or contracts from any entity (if not indicated in item #1 above). ____None Persistence of Anti-SARS-CoV-2 Antibodies in Non-Hospitalized Convalescent Health Care Workers Prevalence of COVID-19 antibodies in healthcare workers at the peak of the pandemic in Mumbai, India: A preliminary study Antibody response to SARS-CoV-2 infection in humans: A systematic review Longitudinal analysis of serology and neutralizing antibody levels in COVID19 convalescents Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Please place an "X" next to the following statement to indicate your agreement:_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.